Your browser doesn't support javascript.
loading
Interest in daily clinical practice of screening for gouty disease in patients with psoriatic arthritis.
Moukarzel, Vanessa; Doussière, Marie; Barbier, Vincent; Menis, Jimmy; Le Monnier, Laure; Salomon-Goëb, Sarah; Aboudiab, Maxime; Goëb, Vincent.
Affiliation
  • Moukarzel V; Department of Rheumatology, University Hospital of Amiens, Amiens, France.
  • Doussière M; Department of Rheumatology, University Hospital of Amiens, Amiens, France.
  • Barbier V; Department of Physical Medicine and Rehabilitation, Centre Hospitalier de Corbie, Corbie, France.
  • Menis J; Department of Rheumatology, University Hospital of Amiens, Amiens, France.
  • Le Monnier L; Department of Rheumatology, University Hospital of Amiens, Amiens, France.
  • Salomon-Goëb S; Department of Rheumatology, University Hospital of Amiens, Amiens, France.
  • Aboudiab M; Department of Rheumatology, Clinique Victor Pauchet, Amiens, France.
  • Goëb V; Department of Rheumatology, University Hospital of Amiens, Amiens, France.
Rheumatol Adv Pract ; 8(3): rkae069, 2024.
Article in En | MEDLINE | ID: mdl-38855627
ABSTRACT

Objectives:

PsA and gout are two prevalent rheumatic diseases, that can be associated as part of a rheumatism known as 'Psout'. Both conditions are associated with cardiovascular (CV) risk, thus their co-occurrence could have significant implications for the management of CV risks and patient care. This study aimed to determine the prevalence of gout within a PsA patient cohort and, consequently, to identify factors associated with this pathological association.

Methods:

This is an observational, descriptive, cross-sectional, single-center study, including patients diagnosed with PsA. Demographic, clinical, biological and imaging data were collected. We identified the proportion of patients simultaneously affected by PsA and gout and compared characteristics between those with and without gout.

Results:

The prevalence of gout among PSA patients was 9.8% (12/122), with a prevalence of 23% for asymptomatic hyperuricemia and 7.4% presenting with specific US signs of gout. Significant associated factors in the univariate analysis included weight, hypertension, diabetes, certain medications (diuretics, aspirin, lipid-lowering agents), impaired renal function, elevated fasting blood glucose, lipid abnormalities and specific US signs of gout.

Conclusion:

Our study has described the existence of patients simultaneously affected by PsA and gout ('Psout'). Performing joint US along with uric acid level measurements in PsA patients can enable personalized therapeutic care.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Rheumatol Adv Pract Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Rheumatol Adv Pract Year: 2024 Document type: Article